SAICoDis: Safety of Argatroban Infusion in Conduction Disturbances
Study Details
Study Description
Brief Summary
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
Primary objective:
To determine change of corrected QT interval (QTc) during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI).
Secondary objectives:
-
Determination of the QTc interval after sufficient wash-out period by ECG-3 which needed to be performed > 8 but ≤ 28 hours after termination of prolonged argatroban infusion.
-
Investigation of dependence of QTc interval on gender and applied doses.
-
Determination of coagulation status during argatroban therapy.
-
Assessment of safety-related events within the scope of anticoagulation with argatroban, for example bleeding events or thromboembolic events.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Argatroban
|
Drug: Argatroban
Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.
If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.
In cases ACT > 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.
As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.
Depending on clinical relevancy further ACT assessments were possible.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Mean difference in QTc interval between ECG-2 and ECG-1 [ECG-2 was recorded immediately after cardiac intervention when patient was fully anticoagulated with argatroban and ECG-1 was recorded at baseline prior to first bolus dose of argatroban (argatroban-free status).]
It was investigated if a mean QTc prolongation of more than 10 ms occurred between ECG-2 and ECG-1
Secondary Outcome Measures
- Proportion of patients with a prolongation of QTc interval to >500 ms at ECG-2 [ECG-2 immediately after argatroban infusion]
Number of patients of ITT population exhibiting QTc interval of > 500 ms
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of stable CAD or unstable angina (troponin negative, i.e. within the normal range for the study site) with low to moderate anatomic risk.
-
Patient required elective percutaneous coronary angioplasty or stent insertion with an approved device in one or more de novo-treated or re-stenotic lesions in native vessels.
-
Patient was on adequate platelet inhibition therapy after having received a loading dose with ASA and clopidogrel before start of intervention (this additional inclusion criterion was introduced with study protocol version 1.6, dated 14.12.2018)
-
Willingness to give written informed consent, written consent for data protection (legal requirement in Germany "datenschutzrechtliche Einwilligung") and willingness to participate and to comply with the requirements of the study protocol.
-
The patient (female/male) was at least 18 years of age.
-
Baseline ECG without changes that impair assessment of QTc interval.
Exclusion Criteria:
-
Patient was indicated for highly complex 3-vessel intervention.
-
The female patient was pregnant (exclusion by routine urine test) or was nursing during therapy period.
-
Patients who were currently participating in another clinical trial or patients who participated in another clinical trial during the last 3 months prior to study start (date of treatment visit).
-
History of drug, alcohol or chemical abuse within 6 months prior to study start.
-
Planned surgical intervention other than study procedure within 7 days after study start.
-
Any condition, which contraindicated the use of argatroban, or endangered the patient if he/she participated in this study.
Factors influencing QTc interval:
- Marked baseline prolongation of QTc interval (repeated demonstration of a QTc interval
450 ms at baseline ECG).
-
A history of risk factors of Torsade de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome).
-
Known intraventricular conduction disturbance.
-
Bradycardia: heart rate < 45 min-1.
-
Electrolyte level outside normal range (according to laboratory's reference values).
-
The use of concomitant medications that interfered with the QTc interval.
-
Intake of digitalis within the last 2 weeks before study start.
-
Acute myocardial infarction or troponin-positive unstable angina.
Factors inhibiting use of argatroban in this study:
-
Intolerance to ingredients of Argatra® (sorbitol).
-
Known cirrhosis, hepatitis, clinically significant hepatic disorder at study start and/or history of clinically relevant hepatic disorder.
-
Current hepatic disorder indicated by laboratory liver profile at screening: Bilirubin, AST/SGOT, ALT/SGPT, gammaGT > 3.0 times upper limit of the normal (ULN).
-
Renal insufficiency indicated by laboratory renal profile at study start: GFR < 35 ml/min.
-
Uncontrolled hypertension (defined as blood pressure >180/120 mmHg).
-
If any form of heparin was taken prior to study start and aPTT ≥ 35 s.
-
Intake of direct oral anticoagulants (DOAC) within 1 month prior to study start.
-
If anticoagulants of type of vitamin K antagonists (VKA) were taken prior to study start and INR >1.2.
-
Platelet count <125 x 109/l.
-
Documented coagulation disorder or bleeding diathesis.
-
Uncontrolled haemorrhage within the past 3 months.
-
Uncontrolled peptic ulcer disease or gastrointestinal bleeding within the past 3 months.
-
Cerebral aneurysm.
-
Haemorrhagic stroke or ischaemic stroke in the past 6 months.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital Frankfurt | Frankfurt am Main | Hessen | Germany | 60590 |
| 2 | Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg | Rotenburg an der Fulda | Hessen | Germany | 36199 |
Sponsors and Collaborators
- Mitsubishi Tanabe Pharma GmbH
Investigators
- Study Director: Deputy General Manager Scientific Medical Affairs, Mitsubishi Tanabe Pharma GmbH
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ARG-E08
- 2016-003521-42